Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Simcere Pharmaceutical Group's EV-to-FCF or its related term are showing as below:
STU:S2P'
s EV-to-FCF Range Over the Past 10 Years
Min: -119.32 Med: -14.53 Max: 102.01
Current: 23.72
During the past 9 years, the highest EV-to-FCF of Simcere Pharmaceutical Group was 102.01. The lowest was -119.32. And the median was -14.53.
STU:S2P's EV-to-FCF is ranked worse than 53.87% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs STU:S2P: 23.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simcere Pharmaceutical Group (STU:S2P) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simcere Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Simcere Pharmaceutical Group's share price for today is €1.38.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.065.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Simcere Pharmaceutical Group EV-to-FCF Related Terms
Simcere Pharmaceutical Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-FCF falls into.
Simcere Pharmaceutical Group's current Enterprise Value is €3,355.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €139.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (STU:S2P) has a EV-to-FCF of 24.11 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Simcere Pharmaceutical Group and its competitors. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #306 out of 568 companies in the Drug Manufacturers industry, placing it in the top 53.9%.
Is Simcere Pharmaceutical Group's EV-to-FCF too high?
Simcere Pharmaceutical Group's current EV-to-FCF is 24.11. The Drug Manufacturers industry median EV-to-FCF is 21.02. Simcere Pharmaceutical Group's value of 24.11 is 14.7% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #306 out of 568 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #306 out of 568 companies for EV-to-FCF. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median EV-to-FCF is 21.02. Simcere Pharmaceutical Group's value of 24.11 is 14.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current EV-to-FCF of 24.11 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EV-to-FCF is 24.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current EV-to-FCF of 24.11. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current EV-to-FCF is 24.11 and 14.7% above the Drug Manufacturers industry median of 21.02. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current EV-to-FCF is 24.11 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.
Key valuation signals for STU:S2P:
EV-to-FCF: 24.11
GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
Industry Position: 14.7% above the Drug Manufacturers median (#306 of 568)
No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for STU:S2P
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S2P has been successfully added to your 
